Publication:
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study

dc.contributor.authorsYildiz, Birol; Kucukarda, Ahmet; Gokyer, Ali; Demiray, Atike Gokcen; Paydas, Semra; Aral, Ipek Pinar; Gumusay, Ozge; Bilici, Ahmet; Akdeniz, Nadiye; Bahceci, Aykut; Demir, Hacer; Esin, Ece; Uyeturk, Ummugul; Okten, Ilker Nihat; Erturk, Ismail; Turk, H. Mehmet; Topaloglu, Ulas Serkan; Basoglu, Tugba; Turhal, Nazim Serdar; Cinkir, Havva Yesil; Menekse, Serkan; Cakmak, Yagmur; Urun, Yuksel; Acar, Ramazan; Kut, Engin; Dal, Pinar; Sakalar, Teoman; Aktepe, Oktay Halit; Karadurmus, Nuri
dc.date.accessioned2022-03-12T22:55:00Z
dc.date.accessioned2026-01-10T17:35:27Z
dc.date.available2022-03-12T22:55:00Z
dc.date.issued2020
dc.description.abstractPurpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients. Methods: In our study, 612 seminomatous GCT patients diagnosed in 22 centers between 01.01.1989 and 03.02.2019 were retrospectively evaluated. Patient interview information, patient files and electronic system data were used for the study. Results: The primary tumor was localized in the right testis in 305 (49.9%) patients and in 307 (50.1%) in the left testis. Mean age of the patients was 36 years (range 16-85 +/- 10.4). The median follow-up period was 47 months (1-298). Recurrence was observed in 78 (127%) patients and 29 (4.7%) died during the follow-up period. Four-year overall survival (OS) was 95.4% and 4-year progression-free survival (PFS) was 84.5%. The relationship between localization and relapse was significant in 197 patients with stage 2 and stage 3 (p=0.003). In this patient group, 41 (20.8%) relapses were observed. Thirty (73.2%) of the relapses were in the right testis and 11 (26.8%) in the left testis. Four-year OS was 92.1% in patients with right tumor; and 98.7% in patients with left tumor (p=0.007). When 612 patients were evaluated with a mean follow-up of 4 years, there was a 6.6% survival advantage in patients with left testicular tumor and this difference was significant (p=0.007). Conclusion: Survival rates of patients with primary right testicular localization were worse compared with left testicular localization, and relapse rates were higher in stage 2 and 3 patients with right testicular localization.
dc.identifier.doidoiWOS:000549861000019
dc.identifier.eissn2241-6293
dc.identifier.issn1107-0625
dc.identifier.pubmed32521916
dc.identifier.urihttps://hdl.handle.net/11424/236608
dc.identifier.wosWOS:000549861000019
dc.language.isoeng
dc.publisherIMPRIMATUR PUBLICATIONS
dc.relation.ispartofJOURNAL OF BUON
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjecttesticular cancer
dc.subjectgerm cell tumor
dc.subjectseminoma
dc.subjectprimary tumor localization
dc.subjectprognosis
dc.subjectsurvey
dc.subjectSURVEILLANCE FOLLOWING ORCHIECTOMY
dc.subjectEUROPEAN CONSENSUS CONFERENCE
dc.subjectRISK-ADAPTED TREATMENT
dc.subjectGERM-CELL-CANCER
dc.subjectSTAGE-I SEMINOMA
dc.subjectTESTICULAR CANCER
dc.subjectDIAGNOSIS
dc.subjectPATTERNS
dc.subjectRELAPSE
dc.titleDoes primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study
dc.typearticle
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage1135
oaire.citation.issue2
oaire.citation.startPage1130
oaire.citation.titleJOURNAL OF BUON
oaire.citation.volume25

Files